^(131)I标记人源抗HBsAg Fab对荷人肝癌裸鼠的放射免疫治疗

ANIMAL EXPERIMENT STUDIES ON THE RADIOIMMUNOTHERAPY OF THE HEPATOMA WITH^(131)I HUMAN anti-HBsAg Fab

目的 1 3 1 I标记人源抗 HBs Ag Fab经腹腔注射治疗荷人肝癌裸鼠移植瘤 ,与 1 3 1 I- S1 0 2 比较 ,评价其作为肝癌放射免疫治疗 (RIT)的可能性。方法 荷瘤裸鼠分为 4组分别经腹腔注射不同放射剂量的 1 3 1 I-抗 HBs Ag Fab、1 3 1 I- S1 0 2 、1 3 1 I-无关 Fab及 PBS。按一定时间间隔作组织分布和血液清除速率测定 ,继续观察 4周 ,以外周血白细胞和血小板数量变化行毒性分析 ,计算各组肿瘤生长抑制率。结果 1 3 1 I-抗HBs Ag Fab被肿瘤区的摄取和在血液中清除速率均明显快于 1 3 1 I- S1 0 2 ,同等剂量下 ,前者抗肿瘤疗效略低 ,但血液毒性明显减轻。结论 人源抗 HBs Ag Fab具有良好的免疫结合活性 ,核素标记后用于 RIT,能够被肿瘤快速摄取并在体内正常组织中快速清除 ,毒性减低 ,具有良好的抗肿瘤疗效 ,是原发性肝癌

Objective To explore the possibility of anti HBsAg Fab as carrier of HCC radioimmunotherapy.Methods The nude mice models with human hepatoma were injected with 131 I human anti HBsAg Fab into the peritoneal cavity (i.p). Radioimmunoimage was taken at different intervals, and tissue distribution was measured. The tumor growth inhibition rate was determined by measurement of tumor volume. The radiotoxicity was evaluated by leukocyte and platelet counts monitored at weekly intervals. Results Tumor uptake and the clearance of 131 I anti HBsAg Fab in normal organs was faster than that of 131 I S 102 . The tumor growth inhibtion rate in 131 I anti HBsAg Fab IP mice was lower slightly than that in 131 I S 102 groups, but the hematologic toxicity was significantly lower than that in the latter. Conclusion [WT5”,6BZ]The human anti HBsAg Fab has a considerable targeting activity, and may be used as a novel humanized vector for targeting therapy of hepatoma